These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Transition state docking: a probe for noncovalent catalysis in biological systems. Application to antibody-catalyzed ester hydrolysis. Tantillo DJ; Houk KN J Comput Chem; 2002 Jan; 23(1):84-95. PubMed ID: 11913392 [TBL] [Abstract][Full Text] [Related]
43. Catalytic antibodies induced by a zwitterionic hapten. Tsumuraya T; Takazawa N; Tsunakawa A; Fleck R; Masamune S Chemistry; 2001 Sep; 7(17):3748-55. PubMed ID: 11575776 [TBL] [Abstract][Full Text] [Related]
44. Natural catalytic antibodies. Paul S Mol Biotechnol; 1996 Jun; 5(3):197-207. PubMed ID: 8837026 [TBL] [Abstract][Full Text] [Related]
45. Crystal structure of the complex of a catalytic antibody Fab fragment with a transition state analog: structural similarities in esterase-like catalytic antibodies. Charbonnier JB; Carpenter E; Gigant B; Golinelli-Pimpaneau B; Eshhar Z; Green BS; Knossow M Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11721-5. PubMed ID: 8524836 [TBL] [Abstract][Full Text] [Related]
46. Lysozyme-catalysed hydrolysis of some beta-aryl di-N-acetylchitobiosides. Lowe G; Sheppard G; Sinnott ML; Williams A Biochem J; 1967 Sep; 104(3):893-9. PubMed ID: 6049930 [TBL] [Abstract][Full Text] [Related]
47. Fidelity in Hapten Design: How Analogous Are Phosphonate Haptens to the Transition States for Alkaline Hydrolyses of Aryl Esters? Tantillo DJ; Houk KN J Org Chem; 1999 Apr; 64(9):3066-3076. PubMed ID: 11674403 [TBL] [Abstract][Full Text] [Related]
48. An approach to sequence-specific antibody proteases. The use of haptens mimicking both a transition state and a distorted ground state. Smith RM; Yuan P; Weiner DP; Dutton CR; Hansen DE Appl Biochem Biotechnol; 1994; 47(2-3):329-42; discussion 342-3. PubMed ID: 7944347 [TBL] [Abstract][Full Text] [Related]
49. Aspects of antibody-catalyzed primary amide hydrolysis. Titmas RC; Angeles TS; Sugasawara R; Aman N; Darsley MJ; Blackburn G; Martin MT Appl Biochem Biotechnol; 1994; 47(2-3):277-90; discussion 291-2. PubMed ID: 7944343 [TBL] [Abstract][Full Text] [Related]
50. Crossreactivity, efficiency and catalytic specificity of an esterase-like antibody. Gigant B; Charbonnier JB; Eshhar Z; Green BS; Knossow M J Mol Biol; 1998 Dec; 284(3):741-50. PubMed ID: 9826512 [TBL] [Abstract][Full Text] [Related]
51. Toward selective covalent inactivation of pathogenic antibodies: a phosphate diester analog of vasoactive intestinal peptide that inactivates catalytic autoantibodies. Nishiyama Y; Bhatia G; Bangale Y; Planque S; Mitsuda Y; Taguchi H; Karle S; Paul S J Biol Chem; 2004 Feb; 279(9):7877-83. PubMed ID: 14676184 [TBL] [Abstract][Full Text] [Related]
52. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies. Ulrich HD; Schultz PG J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442 [TBL] [Abstract][Full Text] [Related]
53. Investigation of a general base mechanism for ester hydrolysis in C-C hydrolase enzymes of the alpha/beta-hydrolase superfamily: a novel mechanism for the serine catalytic triad. Li JJ; Bugg TD Org Biomol Chem; 2007 Feb; 5(3):507-13. PubMed ID: 17252134 [TBL] [Abstract][Full Text] [Related]
54. Structural basis for a disfavored elimination reaction in catalytic antibody 1D4. Larsen NA; Heine A; Crane L; Cravatt BF; Lerner RA; Wilson IA J Mol Biol; 2001 Nov; 314(1):93-102. PubMed ID: 11724535 [TBL] [Abstract][Full Text] [Related]